China Wilson’s Disease Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Wilson disease is a rare genetic disorder characterized by excess copper stored in various body tissues, particularly the liver, brain, and corneas of the eyes. The disease is progressive and, if left untreated, it may cause liver (hepatic) disease, central nervous system dysfunction, and death. The incidence and prevalence of Wilson’s disease in China’s population were approximately 1.96/100,000 and 5.87/100,000 respectively. Although estimates vary, it is believed that Wilson’s disease occurs in approximately one in 30,000 to 40,000 people worldwide. Approximately one in 90 people may be carriers of the disease gene.
China is a growing market for Wilson’s disease due to factors such as increase in China’s incidence rate (1.96/100,000) and increase in China’s prevalence rate (5.87/100,000). Other factors that contribute towards the growth of market are increasing population (China population growth rate is 0.39% in 2020), increase in awareness and rise in healthcare expenditure.
However, there are some restraining factors for growth of Wilson’s disease therapeutics market in China such as underdiagnosis and lack of innovative therapies.